Taconic Biosciences Launches TruIMPORT™ Importation Solution

RENSSELAER, N.Y., May 27, 2021 (GLOBE NEWSWIRE) — Taconic Biosciences, a global leader in providing drug discovery animal model solutions, announces a significant enhancement to the Taconic–Cyagen Model Generation Alliance allowing seamless importation of new genetically engineered models originating in China under the TruIMPORT umbrella.

Researchers at non–profit institutions play a critical role in drug discovery; however, outsourcing animal model generation can be cost prohibitive or a logistical challenge. Hurdles in accessing animal model resources can impede important research. Potential solutions to this problem have traditionally come with trade–offs. Depending on the country of origin, cost effective options can require a lengthy quarantine of the animals or additional breeding to ensure animals meet the required health standards for entry into the institution's animal facility. These additional steps can cost the researcher both time and money.

Originally launched in 2018, the Taconic–Cyagen Model Generation Alliance (the Alliance) for academic and non–profit researchers leverages the talents of two industry–leading companies to create a solution uniquely tailored for non–profit research institutions. Taconic Biosciences has over 65 years of rodent model experience and Cyagen Biosciences is a China–based leader in model generation efficiency and a competitive cost structure. Since its inception, the Alliance has become a recognized leader in providing model generation services to academics and non–profit researchers. TruIMPORT represents an important evolution in this service offering. It allows animal models from China to be imported into United States and European animal facilities while complying with existing vivarium requirements. Providing a set of choices, TruIMPORT allows customers to access efficient model generation with several pricing options depending on desired delivery timeline, health standard, and cohort size.

"Our main goal is to solve problems for our customers," shared Dr. John Couse, vice president of scientific services for Taconic. "While the Alliance has provided efficient model generation for years, importation concerns were a barrier for many customers. By creating multiple options under the TruIMPORT umbrella, customers can now import rodent models from China without quarantine regardless of the requirements of their vivarium."

The TruIMPORT portfolio consists of three importation options: RapidRELAY, RapidCHECK, and RapidEXPANSION. Customers can compare product specifications here to determine which represents the right combination of timeline, health standards, and deliverables to meet their needs.

About Taconic Biosciences, Inc.

Taconic Biosciences is a fully–licensed, global leader in genetically engineered rodent models and services. Founded in 1952, Taconic provides the best animal solutions so that customers can acquire, custom–generate, breed, precondition, test, and distribute valuable research models worldwide. Specialists in genetically engineered mouse and rat models, microbiome, immuno–oncology mouse models, and integrated model generation and colony management services, Taconic operates three service laboratories and six breeding facilities in the U.S. and Europe, maintains distributor relationships in Asia and has global shipping capabilities to provide animal models almost anywhere in the world.

About Cyagen Biosciences, Inc.

Cyagen Biosciences is a leading provider of comprehensive genetically engineered rodent model services. Cyagen utilizes a highly efficient process, including its proprietary AI technology, to design and deliver novel genetically engineered models with precision and competitive pricing. The Cyagen Transgenic Animal Center (CTAC) in China is a state–of–the–art, specific–pathogen free (SPF) barrier facility, which is both AAALAC accredited and OLAW assured. Cyagen has additional locations in the United States, Japan, and China. Since Cyagen's founding in 2005, we have delivered over 78,400 animal models to researchers worldwide and have been cited in over 4,700 publications.

Media Contact:

Kelly Owen Grover

Director of Marketing Communications

518–478–6095

kelly.grover@taconic.com


GLOBENEWSWIRE (Distribution ID 8244120)

GMAC Welcomes Top Latin American Business School as Its Newest Member

RESTON, Va., May 27, 2021 (GLOBE NEWSWIRE) — The Graduate Management Admission Council (GMAC) today announced that EGADE Business School at Tecnolgico de Monterrey has become the Council's latest member. Located in Mexico, the EGADE Business School is selected for its world–class programs and international recognition in and beyond Latin America, adding great representation of the region to the global association that constitutes 229 top business schools around the world.

"EGADE Business School at Tecnolgico de Monterrey has built a globally recognized reputation as the leading Latin American business education institution, committed to empowering entrepreneurial leaders who create shared value and transform society," said Dr. Osmar Zavaleta, interim dean of EGADE Business School. "EGADE is committed to the exchange of ideas and best practices with our global peers and GMAC membership provides a valuable platform for enhancing that exchange other GMAC member schools".

"The pandemic has taught us to be innovative and adaptive in a disruptive environment of an interconnected world," said Sangeet Chowfla, president and CEO of GMAC. "We value the global vision and holistic approach that EGADE Business School brings and look forward to their contributions to the advancement of graduate management education."

EGADE Business Schools is among a select group of institutions internationally to hold the "triple–crown" of excellence from the three leading global accreditation systems for business education quality assessment and continuous improvement: Association to Advance Collegiate Schools of Business (AACSB), Association of MBAs (AMBA), and EFMD Quality Improvement System (EQUIS). For the fourth consecutive year in 2021, EGADE Business School topped the Quacquarelli Symonds (QS) ranking in Mexico and Latin America for its Full–Time MBA in Innovation & Entrepreneurship and Master in Finance programs and appears for the first time as the regional leader for its recently introduced Masters in Management.

To be considered for membership in GMAC, a school must maintain a selective admissions process; offer a master's program in business administration, management subjects or equivalent; and demonstrate support of GMAC's mission through the use of its products and services.

About GMAC

The Graduate Management Admission Council (GMAC) is a mission–driven association of leading graduate business schools worldwide. Founded in 1953, GMAC creates solutions and experiences that enable business schools and candidates to better discover, evaluate, and connect with each other.

GMAC provides world–class research, industry conferences, recruiting tools, and assessments for the graduate management education industry, as well as tools, resources, events, and services that help guide candidates through their higher education journey. Owned and administered by GMAC, the Graduate Management Admission Test (GMAT) exam is the most widely used graduate business school assessment.

GMAC also owns and administers the NMAT by GMAC (NMAT) exam and the Executive Assessment (EA). More than 7 million candidates on their business master's or MBA journey visited GMAC's mba.com last year to explore business school options, prepare and register for exams, and get advice on the admissions process. BusinessBecause and The MBA Tour are subsidiaries of GMAC, a global organization with offices in China, India, the United Kingdom, and the United States.

To learn more about our work, please visit www.gmac.com

Media Contact:

Teresa Hsu
Sr. Manager, Media Relations
202–390–4180 (mobile)
thsu@gmac.com


GLOBENEWSWIRE (Distribution ID 8243682)

Sol-Gel Technologies to Present at Upcoming Jefferies Healthcare Conference and Raymond James Human Health Innovation Conference

NESS ZIONA, Israel, May 27, 2021 (GLOBE NEWSWIRE) — Sol–Gel Technologies, Ltd. (NASDAQ: SLGL), ("Sol–Gel"), a clinical–stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that the Company will present a Company overview and business update at the following upcoming virtual investor conferences:

Jefferies Healthcare Conference (June 1 "" 4, 2021)
Speaker: Dr. Alon Seri–Levy, Chief Executive Officer
Date: Tuesday, June 1, 2021
Time: 8:30 "" 8:55 am EDT
Raymond James Human Health Innovation Conference
(June 21 "" 23, 2021)
Speaker: Dr. Alon Seri–Levy, Chief Executive Officer
Date: Tuesday, June 22, 2021
Time: 10:00 "" 10:30 am EDT

A recording of the webcast of each presentation will be available in the Investors/Events & Presentations section of the Company's website at www.sol–gel.com.

About Sol–Gel Technologies

Sol–Gel is a clinical–stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Sol–Gel leverages its proprietary microencapsulation technology platform for the development of TWYNEO , under investigation for the treatment of acne vulgaris with an NDA filed with the FDA and a PDUFA goal date set for August 1, 2021; and EPSOLAY , under investigation for the treatment of inflammatory lesions of rosacea with an NDA filed with the FDA and a PDUFA goal date set for April 26, 2021. Action on the NDA for EPSOLAY has not yet been taken due to the inability of the FDA to conduct a pre–approval inspection of the production site of EPSOLAY as a result of COVID–19 travel restrictions. The Company's pipeline also includes SGT–210, an early–stage topical epidermal growth factor receptor inhibitor, erlotinib, under investigation for the treatment of palmoplantar keratoderma, and preclinical assets tapinarof and roflumilast. For additional information, please visit www.sol–gel.com.

For further information, please contact:

Sol–Gel Technologies

Gilad Mamlok
Chief Financial Officer
+972–8–9313433

Investor relations
Irina Koffler
LifeSci Advisors
+1–917–734–7387
ikoffler@lifesciadvisors.com


GLOBENEWSWIRE (Distribution ID 8243956)